biotech · Solid Tumors · Pancreatic Cancer · MREO
MEREO BIOPHARMA GROUP
Mereo BioPharma Group plc
MEREO BIOPHARMA GROUP is a biotech organization headquartered in LONDON, USA. It trades on NYSE under ticker MREO. Primary therapeutic focus areas include Solid Tumors, Pancreatic Cancer, Osteogenesis Imperfecta, Metasta
4TH FLOOR, ONE, LONDON, USA HQ
4 Employees
Public company Type
MREO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 4TH FLOOR, ONE, LONDON, USA
- Employees
- 4
- Programs
- 47
- Drugs
- 22
- Patents
- 18
OMP-305B83
Phase 1 · small molecule · Metastatic Colorectal Cancer
OMP-305B83 for Metastatic Colorectal Cancer is a Phase 1 program (small_molecule) at Mereo BioPharma Group plc with 1 ClinicalTrials.gov record(s).
Internal code B83-003
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Mereo BioPharma Group plc
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Metastatic Colorectal Cancer
- Status
- terminated
- Trials
- 1